4D Molecular Therapeutics, Inc. (FDMT) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 10 recommend buying, 3 recommend holding, and 1 recommend selling.
The analyst consensus price target for FDMT is $25.33, representing a +162.2% upside from the current price of $9.66. Price targets range from a low of $17.00 to a high of $33.00.
